Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 21,446 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.65, for a total value of $78,277.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.90, for a total value of $99,446.10.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.04, for a total value of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The stock was sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Price Performance

Shares of GALT stock traded down $0.43 during mid-day trading on Tuesday, hitting $3.45. 905,529 shares of the stock traded hands, compared to its average volume of 684,117. Galectin Therapeutics Inc. has a 52-week low of $1.07 and a 52-week high of $7.13. The stock has a market cap of $222.42 million, a P/E ratio of -5.85 and a beta of 1.03. The stock’s fifty day moving average is $5.34 and its two-hundred day moving average is $4.39.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
• Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
• Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short?term selling pressure. Pomerantz Investor Alert

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GALT. JPMorgan Chase & Co. raised its stake in shares of Galectin Therapeutics by 25.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after acquiring an additional 3,133 shares during the period. Retirement Guys Formula LLC boosted its position in shares of Galectin Therapeutics by 2.7% during the 2nd quarter. Retirement Guys Formula LLC now owns 159,593 shares of the company’s stock worth $337,000 after purchasing an additional 4,250 shares during the period. Stratos Wealth Partners LTD. increased its holdings in Galectin Therapeutics by 17.8% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock valued at $128,000 after purchasing an additional 9,200 shares during the last quarter. Atwood & Palmer Inc. acquired a new stake in Galectin Therapeutics in the 3rd quarter valued at approximately $42,000. Finally, Archer Investment Corp purchased a new stake in Galectin Therapeutics in the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on GALT. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright increased their price target on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Galectin Therapeutics currently has an average rating of “Hold” and an average target price of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.